From Surf Wiki (app.surf) — the open knowledge base
Iomeprol
Chemical compound
Chemical compound
| Field | Value | ||||
|---|---|---|---|---|---|
| image | Iomeprol-Structural Formula V.1.svg | ||||
| image_class | skin-invert-image | ||||
| tradename | Iomervu, others | ||||
| DailyMedID | Iomeprol | ||||
| pregnancy_AU | |||||
| routes_of_administration | Intravenous, intra-arterial | ||||
| ATC_prefix | V08 | ||||
| ATC_suffix | AB10 | ||||
| legal_AU | |||||
| legal_BR | |||||
| legal_CA | |||||
| legal_DE | |||||
| legal_NZ | |||||
| legal_UK | |||||
| legal_US | Rx-only | ||||
| legal_US_comment | |||||
| legal_UN | |||||
| legal_status | Rx-only | ||||
| metabolism | none | ||||
| elimination_half-life | 109±20 min | ||||
| excretion | Kidney | ||||
| CAS_number | 78649-41-9 | ||||
| PubChem | 3731 | ||||
| DrugBank | DB11705 | ||||
| ChemSpiderID | 3600 | ||||
| UNII | 17E17JBP8L | ||||
| KEGG | D01719 | ||||
| ChEBI | 31710 | ||||
| IUPAC_name | 1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide | ||||
| C | 17 | H=22 | I=3 | N=3 | O=8 |
| SMILES | Ic1c(c(I)c(c(I)c1N(C(=O)CO)C)C(=O)NCC(O)CO)C(=O)NCC(O)CO | ||||
| StdInChI | 1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31) | ||||
| StdInChIKey | NJKDOADNQSYQEV-UHFFFAOYSA-N |
| Drugs.com =
| elimination_half-life = 109±20 min
Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.
Iomeprol was approved for medical use in the United States in November 2024.
Side effects
It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium. Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.
Society and culture
Iomeprol is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.
Legal status
Iomeprol was approved for medical use in the United States in November 2024.
Brand names
Iomeprol is sold under the brand name Iomervu.
References
References
- [https://web.archive.org/web/20241204060629/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216017s000,216017s000lbl.pdf fda.gov]
- (2014). "South African medicines formulary". Health and Medical Pub. Group .of the South African Medical Association.
- (2020). "Austria-Codex". Österreichischer Apothekerverlag.
- (1 October 2024). "Novel Drug Approvals for 2024".
- (January 2025). "New Drug Therapy Approvals 2024".
- (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Iomeprol — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report